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Abstract
The use of appropriate growth standards/references is of significant clinical importance in
assessing the height of children with short stature as it may determine eligibility for appropri-
ate therapy. The aim of this study was to determine the impact of using World Health Orga-
nization (WHO) instead of national growth standards/references on height assessment in
short children. Data were collected from routine clinical practice (1998–2014) from nine
European countries that have available national growth references and were enrolled in
NordiNet1 International Outcome Study (IOS) (NCT00960128), a large-scale, non-inter-
ventional, multinational study. The patient cohort consisted of 5996 short pediatric patients
diagnosed with growth hormone deficiency (GHD), Turner syndrome (TS) or born small for
gestational age (SGA). The proportions of children with baseline height standard deviation
score (SDS) below clinical cut-off values (–2 SDS for GHD and TS; –2.5 SDS for SGA)
based on national growth references and WHO growth standards/references were com-
pared for children aged <5 years and children aged5 years. In seven of the countries eval-
uated, significantly fewer children aged5 years with GHD (22%; P<0.0001), TS (21%;
P<0.0001) or born SGA (32%; P<0.0001) had height below clinical cut-off values using
WHO growth references vs. national references. Likewise, among children aged <5 years
in the pooled analysis of the same seven countries, a significantly lower proportion of chil-
dren with GHD (8%; P<0.0001), TS (12%; P = 0.0003) or born SGA (12%; P<0.0001) had
height below clinical cut-off values using WHO growth standards vs. national references.
In conclusion, in NordiNet1 IOS the number of patients misclassified using WHO growth
standards/references was significantly higher than with national references. This study
highlights that, although no growth reference has 100% sensitivity for identifying growth dis-
orders, the most recent national or regional growth charts may offer the most appropriate
tool for monitoring childhood growth in Europe.
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Introduction
Childhood growth and development is routinely monitored using length/height, weight and
head circumference [1]. Abnormal growth patterns may suggest underlying medical or social
conditions requiring further investigation [1]. Deviations from normal growth patterns are
assessed by comparing actual height values with appropriate age- and sex-specific growth refer-
ences, which are universally considered by pediatricians as a crucial tool for correct diagnosis
and timely intervention in many medical conditions [2, 3]. The evaluation of childhood growth
is dependent on the growth charts used, with the recently updated references based on the pop-
ulation under evaluation providing the most accurate reflection of a population’s height. Secu-
lar trends showing incremental increases in growth result in increased average height over
generations [4, 5], especially in affluent populations in which socioeconomic constraints on
growth are minimized [6, 7]. Thus, national growth references are likely to become outdated in
the years after construction, although the secular trend in length/height may be levelling off in
some countries [8]. Consequently, regular updates to all growth references are required to
allow more accurate screening for height disorders [5].
International growth references may be more appropriate than national references in light
of population migration between countries. An early international reference came from the
International Children's Center study, conducted in London, Paris, Zürich, Stockholm, Brus-
sels, Louisville (KY) and Dakar from 1953 onwards, of which the data from Paris are still being
used as growth reference in France [9]. In 2006, multi-ethnic growth standards for children
aged<5 years were released by the World Health Organization (WHO) compiled from the
Multicentre Growth Reference Study, based on growth data collected between 1997 and 2003
from 6669 economically advantaged, breastfed infants and children of non-smoking mothers
from six countries [10]. The premise for constructing these growth standards was that uncon-
strained growth does not vary substantially and therefore one growth curve would be appropriate
to describe normal growth [10]. WHO describes its growth curves as growth standards, provid-
ing normal targets for children’s growth in all countries [11]. These standards differ from growth
references for which the aim is to show how healthy children actually grow in a given time and
place. In 2007, WHO published a reference for children and adolescents aged 5–19 years by
reconstructing the National Center for Health Statistics/WHO growth reference data from 1977
[12]. By 2010, over 100 countries had adoptedWHO standards or references [13].
Accumulating evidence suggests that the height ranges of healthy children aged 0–5 years in
many countries, including Belgium, Canada, Denmark, Norway and Turkey, differ from the
normal ranges according to WHO growth standards [6, 14–20]. The WHO growth standards
provide lower cut-offs for short stature than many of these references, which are generally
newer. As a consequence, the assumption that universal WHO growth standards can be used
globally to accurately screen for linear growth disorders is challenged.
Moreover, the WHO growth references for children aged 5–19 years are based on re-ana-
lyzed data from the USA between 1960 and 1980, and may also provide lower cut-offs due to
the age of the data and because children in the USA historically have been shorter than their
European counterparts.
The aim of the present analysis was therefore to compare potential differences between the
WHO growth standards/references and available national growth references in the Czech
Republic, Denmark, France, Germany, Netherlands, Norway, Sweden, Switzerland and the
UK on height assessment in children with short stature enrolled in NordiNet1 International
Outcome Study (IOS). NordiNet1 IOS (NCT00960128) is a large-scale, non-interventional,
observational study designed to gather long-term data on the safety and effectiveness of Nordi-
tropin1 (recombinant human growth hormone [GH], somatropin; Novo Nordisk A/S,
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Denmark) as prescribed by treating physicians in everyday clinical practice, and to provide
insight into the diseases of the specific endocrine patient populations treated with GH [21].
The implications of using various references and standards in clinical contexts are discussed.
Materials and Methods
Ethics statement
NordiNet1 IOS is conducted in accordance with the Declaration of Helsinki; all patients pro-
vide written informed consent for data collection. All data collected within NordiNet1 IOS are
anonymized. Approval of the local ethics committee or institutional review board at the indi-
vidual center level in accordance with country-specific rules is a prerequisite for each center’s
inclusion in NordiNet1 IOS. The data are completely anonymized prior to access for analysis.
It is mandatory for the parents or guardians of the pediatric patients to provide written
informed consent for the minors’ data to be collected.
Patient population
The patient cohort comprised 5996 pediatric patients with short stature, diagnosed with GHD,
TS or SGA who were enrolled in NordiNet1 IOS and started GH treatment between 1989 and
2014. The majority of patients started GH treatment in the recent years of the study. The
median date for enrollment in NordiNet1 IOS was 2008 for patients aged5 years and 2009
for patients aged<5 years. Clinical diagnosis was based on the investigator’s decision and the
International Classification of Diseases 10th Revision (ICD-10) criteria. Note that patients with
acquired GHD were not included in the analyses, because these children might still have had
normal height at diagnosis [22].
Study design
In this report we evaluate baseline height data from pediatric patients enrolled in nine of the 23
countries participating in NordiNet1 IOS that have available national growth references:
Czech Republic, Denmark, France, Germany, Netherlands, Norway, Sweden, Switzerland and
UK. Eligible patients for the analysis were already on, or about to start, treatment with Nordi-
tropin1 and had baseline height data.
Statistical analysis
Data are presented as means with standard deviation (SD) and percentages. Height standard
deviation scores (SDS) at GH treatment start were calculated using the most recent national
growth chart references (Czech Republic [23]; Denmark [6]; France [9]; Germany [24]; Nether-
lands [7]; Norway [25]; Sweden [26]; Switzerland [27]; UK [28] and WHO growth standards
[10] or WHO references [12]).
The proportions of children aged5 and<5 years with heights below clinical cut-off values
(height below –2 SDS for GHD and TS; –2.5 SDS for children born SGA) were calculated on
country level based on national growth references and WHO growth standards/references. The
difference in the proportion of patients classified with short stature (sensitivity) according to
national or WHO growth standards/references was calculated by the following equation:
difference in sensitivity ¼ nn  nw
N
where nn = number of children with height below clinical cut-off values (national reference);
nw = number of children with height below clinical cut-off values (WHO reference); N = total.
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The equality of the proportions classified with short stature according to national or WHO
growth references was evaluated at country level using the McNemar test for the GHD, TS and
SGA population of children aged5 years. Due to the low number of patients aged<5 years in
most of the countries, the McNemar test could not be applied at country level for all countries
in this population. Hence, the McNemar test was also performed on pooled data of the coun-
tries that had an overall higher short stature classification rate based on the national growth
references than with the WHO growth standards. For consistency a pooled analysis on patients
aged5 years was also applied.
Results
Of the total cohort, 3593 (60%) patients were diagnosed with GHD, 1590 (26%) with short stat-
ure born SGA and 813 (14%) with TS. In both children aged<5 years and5 years, a higher
proportion of boys than girls was observed among children with GHD, but not among short
children born SGA (Table 1). For children aged5 years, age at treatment start was highest for
patients with GHD and lowest for short children born SGA, and in the group aged<5 years,
children with GHD had a lower mean age at GH start than those with TS or born SGA
(Table 1).
Children aged5 years
With the exception of France and the UK, proportionally more children aged5 years across
all three indications by country had height SDS below clinical cut-off values using national
growth references than with WHO growth references (Table 2). In France, proportionally
more children were classified as having height SDS below clinical cut-off values in all three
indications with WHO vs. national growth references. In the UK, the proportion of children
with GHD and TS who were classified as height SDS below –2 was the same as with the WHO
growth references, whilst proportionally more children with SGA were classified as height SDS
below clinical cut-off values with WHO vs. national growth references.
The difference in sensitivity varied between countries (Table 2). Analysis of pooled data
from the seven countries with a higher classification rate (Czech Republic, Denmark, Germany,
Table 1. Baseline characteristics of for patients aged5 and <5 years by indication.
Children with GHD Children with TS Children born SGA
Children aged 5 years, n (%)
Female 969 (33) 647 (100) 538 (47)
Male 1937 (67) − 596 (53)
Mean age at treatment start, years (SD)
Female 10.0 (2.7) 9.8 (3.1) 8.7 (2.6)
Male 10.4 (3.3) – 8.9 (3.0)
Children aged <5 years, n (%)
Female 241 (35) 166 (100) 237 (52)
Male 446 (65) − 219 (48)
Mean age at treatment start, years (SD)
Female 3.3 (1.2) 3.6 (1.0) 4.0 (0.8)
Male 3.5 (1.2) – 4.1 (0.7)
GHD, growth hormone deﬁciency; SD, standard deviation; SGA, small for gestational age; TS, Turner
syndrome.
doi:10.1371/journal.pone.0157277.t001
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Netherlands, Norway, Sweden and Switzerland) based on the national growth references
showed that relatively more patients (22% of children with GHD, 32% of children born SGA
and 21% of children with TS), were classified with height below –2 (or –2.5) SDS using national
growth references when compared with WHO growth references (P<0.0001 across all indica-
tions). The largest difference (national–WHO) for children with GHD was observed in Sweden
Table 2. Number and proportion of children with height SDS below clinical cut-off according to reference and difference and confidence limits for
difference in sensitivity by indication and country for children aged5 years.
Growth hormone deﬁciency
nn/nw/N National proportion below –2 SDS
(%)
WHO proportion below –2 SDS (%) Difference in sensitivity (%) (95%
CI)
Czech
Republic
190/150/211 90 71 19 (14;24)
Denmark 97/73/110 88 66 22 (14;30)
France 537/675/853 63 79 –16 (–19;–14)
Germany 977/696/
1192
82 58 24 (21;26)
Netherlands 22/16/23 96 70 26 (8;44)
Norway 46/32/54 85 59 26 (14;38)
Sweden 130/91/138 94 66 28 (21;36)
Switzerland 157/129/226 70 57 12 (8;17)
UK 73/73/99 74 74 0 (–3;3)
Turner syndrome
nn/nw/N National proportion below –2 SDS
(%)
WHO proportion below –2 SDS (%) Difference in sensitivity (%) (95%
CI)
Czech
Republic
70/45/80 88 56 31 (21;41)
Denmark 31/22/35 89 63 26 (11;40)
France 80/93/144 56 65 –9 (–14;–4)
Germany 244/191/285 86 67 19 (14;23)
Netherlands 19/11/27 70 41 30 (12;47)
Norway 11/10/13 85 77 8 (–7;22)
Sweden 28/21/30 93 70 23 (8;38)
Switzerland 16/15/17 94 88 6 (–5;17)
UK 10/10/16 63 63 0 (0;0)
Small for gestational age
nn/nw/N National proportion below –2.5 SDS
(%)
WHO proportion below –2.5 SDS
(%)
Difference in sensitivity (%) (95%
CI)
Czech
Republic
92/54/108 85 50 35 (26;44)
Denmark 32/22/40 80 55 25 (12;38)
France 209/224/299 70 75 –5 (–8;–2)
Germany 475/305/575 83 53 30 (26;33)
Netherlands 17/10/17 100 59 41 (18;65)
Norway 19/7/25 76 28 48 (28;68)
Sweden 24/8/25 96 32 64 (45;83)
Switzerland 14/9/17 82 53 29 (8;51)
UK 20/21/28 71 75 –4 (–10;3)
nn = number of children with height below clinical cut-off values (national reference); nw = number of children with height below clinical cut-off values
(WHO reference); N = total; SDS, standard deviation score; WHO, World Health Organization.; Clinical cut-off values, below –2 SDS for growth hormone
deﬁciency and Turner syndrome; –2.5 SDS for children with short stature born small for gestational age.
doi:10.1371/journal.pone.0157277.t002
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(difference 28%; 94% vs. 66%; P<0.0001). For children with TS, the largest difference was
observed in the Czech Republic (difference 31%; 88% vs. 56%; P<0.0001). Among short chil-
dren born SGA, the most noticeable difference in the proportions of children aged5 years
with height SDS below –2.5 was observed in Sweden (difference 64%; 96% vs. 32%; P<0.0001).
Children aged <5 years
AsWHO growth standards are designed for use in children aged<5 years, this age group was
analyzed for differences in height SDS between national growth charts and WHO growth stan-
dards. Despite low numbers of children aged<5 years in some countries, a similar pattern of
proportionally more patients with height SDS below –2 (or –2.5 for SGA) was observed using
national growth references compared with WHO growth standards across all indications,
except in France and the UK (Table 3).
When pooling data from the seven countries with higher classification rates with national
references vs. WHO growth standards, a significantly greater proportion of children with GHD
had height SDS below –2 with national references (8%; P<0.0001). Among the children aged
<5 years with TS, analysis of pooled data from the seven selected countries with higher classifi-
cation rates revealed a significantly greater proportion of children with height below –2 SDS
according to national growth references than with WHO growth standards (12%; P = 0.0003)
(Table 3). Among children with SGA aged<5 years, 11% (P<0.0001) more patients were cate-
gorized with short stature using national growth references compared with WHO growth stan-
dards in Germany. Furthermore, analysis of pooled data from the seven selected countries with
higher classification rates showed a significantly higher proportion with height below –2.5 SDS
when evaluated with national vs. WHO growth standards (12%; P<0.0001).
Discussion
We found significant differences across countries in the proportions of children with short stat-
ure and diagnosed with GHD, TS or born SGA using WHO growth standards/references com-
pared with national growth references. Using WHO growth references, significantly fewer
children aged5 years with GHD (22%; P<0.0001), TS (21%; P<0.0001) or born SGA (32%;
P<0.0001) in seven of the countries evaluated (Czech Republic, Denmark, Germany, Nether-
lands, Norway, Sweden and Switzerland) had height below clinical cut-off values than with the
national growth references. In children aged<5 years, a significantly greater proportion of
children with GHD (8%; P<0.0001), TS (12%; P = 0.0003) or born SGA (12%; P<0.0001) had
height below clinical cut-off values with national growth references than with WHO growth
standards in the same seven countries. The available national references used in this study
range with respect to their time of construction from the French national reference collected
from 1953 onwards and published in 1979 [9], to the Danish national reference that was pub-
lished in 2014 [6]. Thus, one would expect that secular trends with increased average height
over generations should reflect differences in cut-offs for short stature, strongly correlated with
the date at which the reference was constructed. The results of this study show that the greatest
differences from the WHO standards/reference were generally observed in those countries
with the most recent published reference data; Czech Republic (2004) [23], Denmark (2014)
[6], Germany (2001) [24], Norway (2013) [25], Sweden (2002) [26], Netherlands (2000) [7]. In
France, which had the oldest national growth reference [9], a smaller proportion of children
across all indications had height SDS below clinical cut-offs using national references than with
the WHO growth standards/references. Our observation is consistent with a recent report by
Scherdel et al., who documented that, with the exception of the first 6 months, the growth of
French children up to 18 years of age and born between 1981 and 2007 was closer to that
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Table 3. Number and proportion of children with height SDS below clinical cut-off according to reference/standard and difference and confidence
limits for difference in sensitivity by indication and country for all patients aged <5 years.
Growth hormone deﬁciency
nn/nw/N National proportion below –2 SDS (%) WHO proportion below –2 SDS (%) Difference in sensitivity (%) (95%
CI)
Czech
Republic
69/62/80 86 78 9 (3;15)
Denmark 27/22/34 79 65 15 (3;27)
France 168/193/
210
80 92 –12 (–16;–8)
Germany 229/214/
260
88 82 6 (3;9)
Netherlands 11/9/14 79 64 14 (–4;33)
Norway 9/6/9 100 67 33 (3;64)
Sweden 39/37/41 95 90 5 (–2;11)
Switzerland 17/16/18 94 89 6 (–5;16)
UK 14/16/21 67 76 –10 (–22;3)
Turner syndrome
nn/nw/N National proportion below –2 SDS (%) WHO proportion below –2 SDS (%) Difference in sensitivity (%) (95%
CI)
Czech
Republic
16/10/22 73 46 27 (9;46)
Denmark 4/3/5 80 60 20 (–15;55)
France 29/33/42 69 79 –10 (–18;–1)
Germany 65//60/77 84 78 6 (1;12)
Netherlands† 1/0/1 100 0 –
Norway† 2/2/4 50 50 –
Sweden† 2/2/3 67 67 –
Switzerland† 1/1/1 100 100 –
UK 8/9/11 73 82 –9 (–26;8)
Small for gestational age
nn/nw/N National proportion below –2.5 SDS
(%)
WHO proportion below –2.5 SDS
(%)
Difference in sensitivity (%) (95%
CI)
Czech
Republic
56/51/58 97 88 9 (1;16)
Denmark 14/12/14 100 86 14 (–4;33)
France 120/135/
144
83 94 –10 (–15;–5)
Germany 162/142/
182
89 78 11 (6;16)
Netherlands 8/4/8 100 50 50 (15;85)
Norway 13/12/15 87 80 7 (–6;19)
Sweden 10/8/11 91 73 18 (–5;41)
Switzerland 7/5/8 88 63 25 (–5;55)
UK 15/16/16 94 100 –60 (–18;6)
nn = number of children with height below clinical cut-off values (national reference); nw = number of children with height below clinical cut-off values
(WHO standard); N = total; SDS, standard deviation score; WHO, World Health Organization. Clinical cut-off values, below –2 SDS for growth hormone
deﬁciency and Turner syndrome; –2.5 SDS for children born small for gestational age.
†Difference in sensitivity and 95% CI not shown due to low N (<5).
doi:10.1371/journal.pone.0157277.t003
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described by the WHO growth standards/references than to the French national reference used
in our study [29].
Although the use of an appropriate growth standard/reference is important to detect short
stature, growth charts are never ideal, especially as they are dependent upon accurate height
measurements [30]. Moreover, it should be considered that growth charts form only a part of
the clinical armory for detecting diseases or conditions with short stature [29].
Although WHO advocates the use of a single height-for-age chart worldwide [31, 32], sev-
eral studies have demonstrated significant differences in height assessed using WHO and
national height-for-age references [15, 28]. In a meta-analysis of data published in studies from
55 countries, involving over 11 million children aged<5 years, 20% of all values for mean
height SDS were0.5 SD from the means in WHO growth standards [33] and 44% of means
for boys and 48% of means for girls were at least ±0.25 SD from corresponding mean values in
WHO standards at four or more time points. Among outliers, Europeans were generally above
0.5 SD, and children from Saudi Arabia and Asian Indians were below –0.5 SD, suggesting
inter-population differences that warrant consideration when evaluating patients with short
stature [33]. In a large German study, Rosario et al. [15] demonstrated that mean heights for
boys and girls aged5 years were at the 60th and 62nd percentiles of WHO growth standards,
respectively. On the basis of these findings, those authors recommended use of national growth
curves over WHO growth standards [15]. Moreover, in Australia, Hughes et al. [34] docu-
mented that use of WHO growth standards to assess height was associated with consistent
under-diagnosis of short stature, indicating that Australian children are taller than the WHO
reference population.
Only a few studies have evaluated the impact of using WHO height standards/references
compared with national references in pediatric diseases. Bonthuis et al. [35] found that 33%
and 34% of 3402 children with end-stage renal disease from 13 European countries would be
classified as short for age using WHO or Center for Disease Control and Prevention growth
references, respectively, compared with 44% meeting the criteria using recent national or
derived Northern and Southern European growth references. Likewise, Saari et al. [36] demon-
strated a significantly (P0.001) higher sensitivity for detecting short stature among girls with
TS using population-specific growth references than using WHO growth standards.
The secular trend in growth mandates regular updating of growth references and updated
single-country height-for-age references can be assumed to provide optimal reference informa-
tion. In the present analysis we have demonstrated a marked deviation fromWHO growth
standards/references for the countries with the most recently updated growth references (for
example, Denmark and Norway [6, 25]), whereas France, using older growth references [9],
classified a lower proportion of children with short stature than WHO standards/references. A
key argument for the use of WHO growth standards is that breastfed children of non-smoking
mothers represent a healthier population with a differential, healthier growth pattern. How-
ever, recent national cohorts including breastfed children of non-smoking mothers also
showed increased height vs. WHO standards [6, 14].
As assessment of a child’s height in relation to the height distribution of the peer population
is one of the best indicators of his or her general health and well-being [2], the use of outdated
growth references may have significant implications for individual patients [37]. More children
will meet the criteria for short stature when a reference population is taller than that used to
develop WHO growth standards/references. Likewise, deviation from normal growth is under-
diagnosed when outdated national references, such as those from France (1979) and the UK
(1990), are used for the assessment of short stature.
The variations in height assessments in our study highlight the complexities of growth and
growth monitoring. In addition to genetics, health, nutritional status, and psychosocial and
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environmental factors, differences in the rate of secular changes in growth between countries
may all have an impact on population height [33].
Strengths of our study include the large sample size and the robustness of our findings
across several European countries with updated growth references, even in children aged<5
years. Possible limitations may include lack of adjustment for ethnicity or immigrant popula-
tions, which may be important determinants of growth [38] and the lower numbers of children
per indication aged<5 years, which restricted the use of statistical models for comparison of
data on country level. In addition, data on the genetic composition of children with Turner
syndrome were not available. However, descriptive data and analysis on pooled data indicated
that the overall trends were the same as those described for the total patient cohort.
Conclusions
The use of inappropriate growth standards/references to assess short European children may
lead to significant reclassification to normal height, potentially delaying or leading to missed
diagnosis of a growth disorder. This may prevent the timely identification of an underlying
medical condition in children with short stature. Although the use of growth references may
have limitations, mainly stemming from the secular trends in growth patterns and population
differences, our data suggest that updated national or regional growth references may offer the
most suitable option for monitoring the growth of European children with short stature.
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